ABSTRACT
Bone marrow transplantation from a histocompatible matched sibling donor was established as a curative therapy for lethal congenital immunodeficiencies with the successful transplant of a patient with severe combined immunodeficiency (SCID) (1) and another child with WiskottAldrich syndrome (WAS) (2) in 1968. Over the ensuing 35 years, our knowledge of hematopoietic stem cell transplantation (SCT) has increased greatly. As our knowledge of transplantation and immunology has expanded, patients with many other primary immunodeficiencies (PIDs) (Table 1) have undergone SCT (4-7). Furthermore, the use of alternative donors and donor stem cell sources, when matched sibling donors are not available, has greatly increased the number of individuals who benefit from this procedure (8-10).
